Pestalozzi has taken on partners Petra Hanselmann and Pascal Richard as well as Markus Winkler as counsel. With this new additions, the law firm is further strengthening its full-service in the areas of m&
Radicant, the BLKB subsidiary new firm, has received a FINMA banking licence. Radicant is the first sustainable, collaborative and fully digital bank in Switzerland with a strong focus on personalized and sustainable financial solutions. Founded
Joël Doswald joins Wenger Vieli as new senior associate at the Tax department. As Tax advisor, Doswald counsels family-owned businesses along with the individuals involved in national as well as international tax issues. Thanks
Wenger Vieli advised Swiss Startup Group on obtaining a FINMA licence as manager for collective assets for its subsidiary Serpentine Ventures. Serpentine Ventures is Switzerland’s first FINMA licensed venture capital asset manager managing a
Niederer Kraft Frey advised CoinShares, a Europe digital asset investment firm with over USD 1.6 billion in AUM, in connection with the listing of the company’s physically-backed Solana and Cardano exchange traded products (ETPs) on
Solstis has joined the BKW Group following its acquisition by BKW Building Solutions, a BKW Group company. This acquisition is part of the Group’s growth strategy. BKW Building Solutions is a regionally based network
Credit Suisse Group has priced the issuance of USD 1.65 bn 9.750 per cent. Perpetual Tier 1 Contingent Write-down Capital Notes. The Notes are «high trigger» regulatory capital instruments that are eligible to fulfill
Niederer Kraft Frey has advised Kernkraftwerk Leibstadt on the placement of a CHF 200 million bond (CHF 175 million plus CHF 25 million top up) with a term to maturity of 5 years. The net proceeds will be used
Riverside Company, a global private equity investor focused on the smaller end of the middle market, has announced the acquisition of Geneva-based Actando. The software and services company Actando is a global learning organization that
VectivBio Holding a clinical-stage biopharmaceutical company, has announced a combined gross proceeds from public offering and private sale of USD 50 million. On one side, the company has announced the pricing of a follow-on public offering
